Related Party Transactions (Details Narrative) - USD ($)						3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 14, 2022	Nov. 08, 2021	Feb. 10, 2021	Mar. 30, 2020	Aug. 13, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Value of common stock shares issued									$ 475,000
Warrants exercise price						$ 0.4132		$ 0.4132
Fair value of warrants						$ 168,000		$ 255,000
Proceeds from issuance costs									$ 496,000
Common stock held						250,000		250,000
Secured Convertible Promissory Note [Member]
Increase in line of credit								2,000,000.0
Maximum borrowing capacity						$ 1,000,000.0		$ 1,000,000.0
Line of credit, expiry date								Feb. 14, 2024
2022 Warrants [Member]
Warrant to purchase share of common stock						6,502,442		6,502,442
Warrants exercise price								$ 0.71
Warrants ecercise price								$ 0.88
Common Stock [Member]
Number of common stock shares issued									242,000
Value of common stock shares issued
Proceeds from issuance costs								$ 10,000,000.0
2020 Loan Agreement [Member]
Line of credit, term				18 months
Maximum borrowing capacity				$ 8,000,000.0		$ 8,000,000.0		$ 8,000,000.0
Warrant to purchase share of common stock				3,670,663		3,670,663		3,670,663
Stock issued during period, shares				28,500
Line of credit facility, current borrowing capacity				$ 3,000,000.0
Line of credit, expiry date				Mar. 30, 2023				Mar. 30, 2023
Line of credit facility, description				other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due;
2020 Loan Agreement [Member] | Warrant [Member]
Warrants exercise price								$ 0.70
Warrants ecercise price								$ 1.895
2022 Secured Convertible Promissory Note and Security Agreement [Member]
Line of credit, term	12 months
Maximum borrowing capacity	$ 7,160,000
Line of credit	13,160,000
Security Agreement [Member]
Line of credit facility, description								if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date
Registration Rights Agreements [Member]
Line of credit facility, description								AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence.
Juvenescence [Member]
Line of credit facility								$ 10,160,000
Warrant to purchase share of common stock						6,502,442		6,502,442
Reimbursement								$ 280,000
Accounts payable						$ 69,000		$ 69,000		$ 70,000
Juvenescence [Member] | 2019 Loan Agreement [Member]
Line of credit facility					$ 2,000,000.0
Line of credit, term					18 months
Increase in line of credit		$ 1,000,000.0	$ 4,000,000.0
Maximum borrowing capacity	7,000,000.0	$ 7,000,000.0
Number of common stock shares issued										19,000
Value of common stock shares issued										$ 56,000
Origination Fee	160,000
Warrant to purchase share of common stock					150,000
Warrants exercise price					$ 2.60
Fair value of warrants					$ 236,000
Juvenescence [Member] | 2022 Secured Convertible Promissory Note and Security Agreement [Member]
Line of credit facility	$ 8,160,000
Related party transaction description								(i) issuing additional shares in a transaction involving the sale, issuance, or potential issuance by the issuer of common stock (or securities convertible into common stock) equal to 20% or more of stock outstanding (determined as of the date of the particular transaction agreement) for less than the greater of book or market value of the Exchange listed common stock (the “20% Rule”) and (ii) issuing shares that will result in a change of control of the company (the “Change of Control Rule”). While the Exchange has not defined “change of control”, the Exchange considers any issuance of stock to be subject to the Change of Control Rule if the issuance of stock would result in a stockholder holding 50% or more of a company’s outstanding stock. The Secured Note contains a “19.9 % blocker” provision and a “change of control blocker”
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member]
Line of credit						10,160,000		$ 10,160,000
Line of credit facility, remaining borrowing capacity						3,000,000.0		3,000,000.0
Reverse Ratio [Member]
Indebtedness						$ 15,000,000.0		$ 15,000,000.0